Amphista
Cambridge, GB · 7 known investors
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.
Biotech
Founders & leadership
LM
Louise ModisChief Executive Officer
MP
Martin PassChief Development Officer
GB
Giles BrownExecutive VP Drug Discovery
Investors · 7
In the news
Frequently asked questions
- What does Amphista do?
- Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.
- Who are Amphista's investors?
- Amphista's investors include Advent Life Sciences, Novartis Venture Fund, Dementia Discovery Fund, European Investment Fund, Forbion, Gilde Healthcare, Scottish Investment Bank.
- Where is Amphista headquartered?
- Amphista is headquartered in Cambridge, GB.